Asset Details
Do you wish to reserve the book?
Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch
Do you wish to request the book?
Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch
2007
Overview
The skin is an attractive target for vaccine delivery. Adjuvants and antigens delivered into the skin can result in potent immune responses and an unmatched safety profile. The heat- labile enterotoxin (LT) from Echerichia coli, which acts both as antigen and adjuvant, has been shown to be delivered to human skin efficiently when used in a patch, resulting in strong immune responses. Iomai scientists have capitalized on these observations to develop late-stage products based on LT. This has encouraged commercial-level product development of a delivery system that is efficient, user-friendly and designed to address important medical needs. Over the past 2 years, extensive clinical testing and optimization has allowed the patch to evolve to a late-stage product. As a strategy for approval of a revolutionary vaccine-delivery system, the singular focus on optimization of LT delivery has enabled technical progress to extend patch-vaccine product development beyond LT. The field efficacy of the LT-based travelers' diarrhea vaccine has validated this approach. The discussion of transcutaneous immunization is unique, in that any consideration of the adjuvant must also include delivery, and the significant advances in a commercial patch application system are described. In this review, we integrate these concepts, update the clinical data and look to the future.
Publisher
Taylor & Francis,Expert Reviews Ltd,Informa Healthcare
Subject
Adjuvants, Immunologic - administration & dosage
/ Animals
/ Bacterial Toxins - administration & dosage
/ Bacterial Toxins - immunology
/ Enterotoxins - administration & dosage
/ Escherichia coli Proteins - administration & dosage
/ Escherichia coli Proteins - immunology
/ Humans
/ Needles
/ patch
